RxDoctor Payments Data

Kayla Wolf, APRN

Family · Rogers, ARNPI 1578134946

Payments from drug & device makers

$867in general payments, 2019–2025

Across 37 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$183
  • AstraZeneca$166
  • AbbVie$139
  • Amgen$81
  • Lilly USA, LLC$80
  • Exact Sciences$53
  • plus $164 from 6 others

What the payments were for

  • Food & beverage$867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$867 in reported general payments places this provider in the 65th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$2,679
Medicare patients
27
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol105$119,031
OzempicSemaglutide62$101,987
TrulicityDulaglutide14$32,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$24,202
TradjentaLinagliptin27$18,892
Spiriva HandihalerTiotropium Bromide27$18,736
JanuviaSitagliptin Phosphate15$17,884
JardianceEmpagliflozin13$16,836
Spiriva RespimatTiotropium Bromide19$12,906
Tresiba Flextouch U-100Insulin Degludec17$12,465
EliquisApixaban18$12,366
DuleraMometasone/Formoterol23$8,311
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,673
Levemir FlexpenInsulin Detemir11$6,530
LinzessLinaclotide12$5,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$166$124,537120 claims
Novo NordiskOzempic$183$101,98762 claims
Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat$15$48,63359 claims
Lilly USA, LLCTrulicity, Humalog$80$33,59828 claims
GSKTrelegy Ellipta, Breo Ellipta$34$29,38534 claims
PfizerEliquis$18$12,36618 claims
AbbVieLinzess$139$5,57412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,103 family providers in Arkansas.

Other family in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →